Carboplatin and paclitaxel as first‐line treatment of unresectable or metastatic esophageal or gastric cancer. Issue 8 (25th August 2014)

• Record Type: Journal Article
• Authors: Prithviraj, G. K.; Baksh, K.; Fulp, W.; Meredith, K.; Hoffe, S.; Shridhar, R.; Almhanna, K.
• Is Part Of: Diseases of the esophagus. Volume 28:Issue 8(2015)
• Page Start: 782
• Page End: 787
• Publication Date: 2014-08-25
• Subjects: carboplatin -- esophageal cancer -- paclitaxel; Esophagus -- Diseases -- Periodicals; 616.32
• DOI: 10.1111/dote.12279
• Languages: English
• ISSNs: 1120-8694

Abstract

Summary: Survival in patients with metastatic esophageal and gastric cancer is dismal. No standard treatment has been established. Carboplatin/paclitaxel is active in both advanced gastric and esophageal cancer. Here we retrospectively present our single center experience. Between 1998 and 2013, a total of 134 patients with metastatic esophageal and gastric adenocarcinoma treated with carboplatin/paclitaxel (carboplatin predominantly area under the curve 5 and paclitaxel predominantly 175 mg/m 2 ) every 3 weeks as first‐line therapy were identified. Baseline characteristics, response to therapy, toxicities, and survival in this patient population were evaluated. Overall survival was defined as date from diagnosis to death or last follow up, and progression‐free survival was defined at time from cycle 1 to, progression or last follow up. Kaplan–Meier curves were fit to estimate overall and progression‐free survival. Of the 134 patients evaluated, the median age at diagnosis was 65 years. Disease control rate was 62.6% (complete response: 11%, partial response: 28%, stable disease: 33%). Median overall survival from date of initial diagnosis was 15.5 months (95% confidence interval [CI] 1.06–1.5). Median progression‐free survival from date of initiation of carboplatin and paclitaxel was 5.3 months (95% CI 0.34–0.5). Grade III or greater toxicity occurred in 26.1% of patients. The most common grade III toxicities were neutropenia and neuropathy, present in 14.2% and 3.7% of the total study population, respectively. In patients with metastatic or unresectable esophageal or gastric cancer, the combination of carboplatin and paclitaxel is well tolerated with comparable overall survival and progression‐free survival to existing regimens in this population.